Summary.-Cell-mediated cytotoxicity (CTX) was studied in meningioma patients before and within 2 weeks of complete excision of the tumour, using the [3H]-proline microcytotoxicity test. Three of 7 patients tested before surgery showed specific CTX, 2 revealed a " non-specific " (tumour-unrelated) response, and 2 were nonreactive. After surgery, CTX decreased from 84 to 50% in one patient and became negative in 2 others previously positive. One of 2 patients showing " non-specific" CTX preoperatively became positive, while the other remained unchanged.
MANY reports have been published estimating immune responses against human brain tumours in vitro (Brooks et al., 1972; Levy, Mahaley and Day, 1972; Wahlstrom, Saksela and Troupp, 1973; Meyer-Rienecker et al., 1975) . Although these reports demonstrate that the brain can no longer be regarded as an " immunologically privileged site " (Medawar, 1948) , results are still conflicting.
In order to eliminate at least some of the technical problems, we used a well-defined [3H]-proline microcytotoxicity test (Bean et al., 1973) . A benign tumour (meningioma) was initially selected for study, since such lesions are less heterogenous and easier to grow in tissue culture than malignant tumours of the central nervous system (CNS). Meningiomas are common intracranial tumours and are usually excised completely. Most of these tumours have a definite chromosome loss, both in vivo and in vitro (Zankl and Zang, 1972) .
In a previous study, we demonstrated the occurrence of a specific cytotoxic immune response in about 65% of postoperative meningioma patients tested in vitro (Pees and Seidel, 1976) . The aim of the present study was to test the effect of surgery on cellular cytotoxicity (CTX). Part of the study also assessed the influence of treatment with dexamethasone (DXM), a drug now widely used in neurosurgery of CNS tumours.
MATERIALS AND METHODS
Target celtt (T) .-Biopsy specimens of CNS tumours were carefully dissected, washed several times and trypsinized. Primary Correspondence: Dr H. W. Pees, I . Medizinische Universitatsklinik, D-6650 Homburg/Saar, West Germany.
cultures were established either from singlecell suspensions or small pieces of tumour. All cultures were maintained in Eagle's minimal essential medium (MEM) with 1% non-essential amino acids (NEAA) supplemented with 2 mm glutamine, streptomycin (100 ,tg/ml), penicillin (100 i.u./ml), and 15% foetal calf serum (FCS). All meningioma explants grew rapidly, whereas glioblastoma tissues were much more difficult to establish, either on account of the proliferation of contaminating fibroblasts or the paucity of tumour cells after one or two passages. One line originating from a glioblastoma multiforme (I.F.) appeared satisfactory by morphological criteria and growth characteristics, and was used as a control. Normal fibroblasts were obtained from explants of skin biopsy specimens.
All cultures were routinely checked for fungal and bacterial contamination, and discarded if infected. The cells were frozen in liquid N2 as early as possible, and tested during the first few passages.
Effector cells (E).-For cytotoxicity experiments, lymphoid cells were purified from venous blood by defibrination, sedimentation with gelatin, and incubation on a nylon wool column for 30 min at 37°C to remove adherent cells. After elution from the column, the cells were treated with 0.84% NH4Cl and washed x 3 (O'Toole et al., 1972a) . The final culture medium was MEM with 10% human AB Rh-+ serum.
Viability was always greater than 95% as judged by trypan blue exclusion.
For determination of the proliferative response to phytohaemagglutinin (PHA), peripheral blood lymphocytes were separated by defibrination and centrifugation over a discontinuous Ficoll-Hypaque gradient (Boyum, 1968) . The cells were washed x 3 and final suspensions prepared in MEM containing 10% human AB Rh+ serum.
Sera.-Sera were obtained from clotted aseptically drawn venous blood. Red cells were removed by centrifugation at 900 g for 10 min. All sera were heat-inactivated at 56°C for 30 min, sterilized by millipore filtration, and stored in aliquots at -20°C until use. In some experiments, several normal sera from AB Rh+ donors were pooled.
Each serum was first tested for its ability to support growth of target cells and mitogenstimulated lymphocytes.
Microcytotoxicity test.-Labelling of target cells with [3H]-proline was performed as described elsewhere (Bean et al., 1973 (Fig. 1) .
Seven meningioma patients could be tested both before and shortly after surgery. Three showed a specific destruction of meningioma cells (27-84% CTX) when tested preoperatively, 2 were negative and another 2 met the criteria of a " non-specific " response. It is noteworthy that in these latter cases an almost total destruction of tumour cells was observed early in the incubation period. This phenomenon did not correlate with transfusion history, recent infection or the composition of effector cells. "Non-specific " CTX on meningioma cells decreased only slightly after surgery, whereas allogeneic fibroblasts were much less affected postoperatively.
As can be seen from Table I and Fig. 2 , negative cases remained unchanged, and 2/3 patients positive before surgery became negative. Experiments were also performed using glioblastoma target cells (I.F.) to investigate the specificity of the reaction further. In no case did lymphocytes reacting specifically on meningioma targets show a significant destruction of glioblastoma cells.
Influence of treatment with dexamethasone on CTX
No correlation could be found between of this inhibitory effect, lymphocytes from patient K.L. were incubated on allogeneic fibroblasts and meningioma cells using both normal and autologous serum. Since in normal serum destruction of all targets occurred and autologous serum was able to suppress this effect, the conclusion seems to be justified that this blocking activity was "non-specific".
Relation to blood group sub8tances Agglutination of contaminating red blood cells in the effector cell preparations by certain test sera was observed, as expected from blood group differences. A cytotoxic effect, however, did not occur even in those combinations where test sera contained isoantibodies directed against blood group antigens of the target cell donor (ABO system). No attempt was made to test the expression of these antigens on the target cells in question. (Table IV) . There was no history of multiple pregnancies or transfusions in this donor.
DISCUSSION
Previous studies of other authors (O'Toole et al., 1972b) and from our own laboratory (Pees and Seidel, 1976 ) have suggested that cell-mediated immunity as measured in vitro by a microcytotoxicity assay might depend on the presence of a critical tumour mass in the body. In meningioma patients the highest response rate was seen during the first 3 weeks. The observation of a rapidly disappearing CTX in one patient tested on several occasions postoperatively prompted us to test the effect of surgery on CTX in these tumours.
Our results demonstrate a marked decrease or even disappearance of CTX following surgery. In all patients the tumour had been removed completely. However, since there is now widespread conviction that dexamethasone may dramatically reduce peri-tumoral oedema (Fishman, 1975) , a considerable number of patients with CNS tumours will be treated with this drug for a certain period before and after surgery. Thus, most of our patients were receiving treatment already when they were admitted to the department of neurosurgery. We therefore decided to test all patients during therapy, though we were aware that the immunological situation would be even more complex. phenomenon is due to sequestration of peripheral T cells into the bone marrow (Cohen, 1972; Fauci and Dale, 1974; . Therefore, measuring T-cell function in the peripheral blood, in common with ability to respond to PHA (Lohrmann, Novikovs and Graw, 1974) , should provide a means of investigating this redistribution effect. However, we were not able to demonstrate any significant difference in the response to PHA before and after surgery, i.e. after prolonged treatment with DXM.
Taken together, the following explanations should be considered:
(a) DXM does indeed suppress CTX by depletion of T cells. However, PHA stimulation is not an appropriate means to test this hypothesis. Hydrocortisone might selectively deplete functional subpopulations, i.e., Con A-and Pokeweedresponsive cells, without significantly affecting PHA-responsiveness (Fauci and Dale, 1974) .
(b) DXM does not inhibit lymphocyte function when administered in the dosage used in our study. Unfortunately, exact information in regard to equivalent doses of OHC and DXM in this context is still lacking.
(c) Our finding of a " normal " cytotoxic response during treatment with DXM might indicate a major role for a steroid-insensitive, possibly thymusindependent lymphocyte. Indeed, the effector cell in the cytotoxic system described here is supposed to be a " null cell ", i.e. a thymus-independent, IgGnegative cell with receptors for C3 and Fc (O'Toole et al., 1974; Brier, Chess and Schlossman, 1975) . Under certain conditions such as neoplasia and prolonged treatment with prednisone and cytostatics, the percentage of "null cells" in the peripheral blood is elevated (Yu et al., 1974) .
Our studies are in contrast with other reports, where high degrees of CTX were still detectable at more than 10 years after successful surgery of malignant brain tumours . Technical as well as immunological differences between benign and malignant CNS tumours might account for some of these divergent results. Brooks et at. (1972) described an inhibition of the blastogenic response to tumour-specific membrane antigens and PHA by autologous sera in patients with intracranial tumours, including meningiomas. Only one patient in our series had such a suppressor activity directed against allogeneic lymphocytes and associated with the IgG fraction of his serum. Thomas, Lannigan and Behan (1975) found depression of PHA-induced protein synthesis in gliomas, but not in benign brain tumours.
The blocking activity which could be demonstrated in some sera in the cytotoxic assay turned out to be not specific for meningiomas. Interestingly, with one exception, the same sera did not inhibit response to PHA. Blocking phenomena are due to different substances, like specific antigens, complexes of antigen and antibody, and totally unrelated immune complexes acting via the Fcreceptor (Currie and Basham, 1972; Saksela, Penttinen and Pyrhonen, 1974) . We have shown recently that immunosuppression in cancer sera is related to the presence of micromolecular fibrinogen degradation products (Girmann et al., 1976) . However, since these substances not only inhibit CTX of meningioma patients (Pees and Girmann, unpublished observations) but also strongly suppress PHA-stimulation, they are less likely to be involved here.
Another intriguing question is the phenomenon of CTX directed against targets of different histogenic origin, often referred to as " non-specific " CTX. Two patients in our study showed this type of response. It has been claimed (Unsgaard and O'Toole, 1975 ) that myeloid precursor cells, often found in the peripheral blood of patients with metastases, are responsible for the killing of unrelated target cells in vitro. Our patients did not have clinical evidence of metastasis, weight loss or haematological abnormalities. We should emphasize that the term " non-specific " is by no means equivalent to "nonimmunological" and should not preclude careful analysis of this phenomenon.
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